About
SyNoesis Therapeutics is a precision-medicine SME integrating AI-enabled clinical decision-support, multimodal biomarkers, and therapeutic development to improve the early detection and management of chronic and neurological diseases, and advance First-in-Class treatments.
On the digital-health side, SyNoesis has developed a TRL6 clinical-note NLP engine validated on large, real-world, multilingual EHR datasets, supporting early risk stratification and personalised care. This expertise is being expanded by integrating functional and molecular biomarkers to build multimodal decision-support companions that can be deployed into routine clinical workflows.
In parallel, SyNoesis advances a focused preclinical drug development pipeline in neurodegeneration (and selected oncology indications), allowing mechanistic insights and biomarker discoveries to directly inform its AI-driven stratification tools. Through this integrated strategy, SyNoesis aims to contribute to equitable, data-driven personalised medicine and scalable clinical implementation across European regions.
Type of Cooperation
Research collaborationCo-developmentClinical validationConsortium partners
Sector
Health dataAIDiagnostics
Development Stage (TRL)
TRL 6
Therapeutic Area
BioinformaticsDiseases of the nervous system / neurologyEndocrine/nutritional/metabolic diseasesMental and behavioural disorders / psychiatry / psychologyProteomics